Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 11, 925 - 927 (2005)
doi:10.1038/nm0905-925
Masters of angiogenesis
Robert M Strieter1
- The author is in the Departments of Medicine, Pathology and Laboratory Medicine, and Pediatrics, Division of Pulmonary and Critical Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1786, USA. e-mail: rstrieter@mednet.ucla.edu
Abstract
Fresh approaches are needed for antiangiogenesis therapies that target blood vessel growth in tumors. Knocking down multiple regulators of angiogenesis might provide a way forward (pages 992–997).
The concept of treating tumors by cutting off angiogenesis, the process of new blood vessel growth, is powerful. But in practice, results of clinical trials of angiogenesis inhibitors—such as bevacizumab, the monoclonal antibody to vascular endothelial growth factor (VEGF) have not been overwhelming1, 2.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mastering innate immunityNature Medicine News and Views (01 May 2003)
Angiogenesis: escape from hypoxiaNature Medicine News and Views (01 May 2009)
RESEARCH
Induction of interleukin-8 preserves the angiogenic response in HIF-1α?deficient colon cancer cellsNature Medicine Letter (01 Sep 2005)
HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cellsOncogene Original Article
See all 10 matches for Research